Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Low-density lipoprotein apheresis in the treatment of atherosclerosis and other potential uses.

Literature DB >> 11177660

Low-density lipoprotein apheresis in the treatment of atherosclerosis and other potential uses.

Abstract

This review concerns the clinical impact of low-density lipoprotein (LDL) apheresis for patients with refractory hypercholesterolemia. We examine and provide examples of investigations that have demonstrated the clinical benefits of LDL apheresis. In addition to benefits derived from the stabilization or regression of arterial lesions, we highlight other possible mechanisms related to clinical improvement. We also discuss the potential advantages of lipid apheresis for the treatment of patient populations other than those characterized by severe hypercholesterolemia and premature coronary heart disease.

Entities: Chemical Disease Species

Mesh：

Substances：
Lipoproteins, LDL

Year: 2001 PMID： 11177660 DOI： 10.1007/s11883-001-0052-5

Source DB: PubMed Journal: Curr Atheroscler Rep ISSN： 1523-3804 Impact factor: 5.113

49 in total

Review 1. Idiopathic sudden sensorineural hearing loss.

Authors: D E Mattox; C A Lyles
Journal: Am J Otol Date: 1989-05

Review 2. H.E.L.P. apheresis therapy in the treatment of severe hypercholesterolemia: 10 years of clinical experience.

Authors: D Seidel
Journal: Artif Organs Date: 1996-04 Impact factor: 3.094

3. The Microspheres based Detoxification System (MDS). A new extracorporeal blood purification technology based on recirculated microspherical adsorbent particles.

Authors: C Weber; C Rajnoch; F Loth; H Schima; D Falkenhagen
Journal: Int J Artif Organs Date: 1994-11 Impact factor: 1.595

4. Changes in bradykinin and prostaglandins plasma levels during dextran-sulfate low-density-lipoprotein apheresis.

Authors: S Kojima; M Ogi; Y Yoshitomi; M Kuramochi; J Ikeda; M Naganawa; H Hatakeyama
Journal: Int J Artif Organs Date: 1997-03 Impact factor: 1.595

5. Low-density lipoprotein apheresis therapy during pregnancy.

Authors: L Cashin-Hemphill; M Noone; J F Abbott; C A Waksmonski; R S Lees
Journal: Am J Cardiol Date: 2000-11-15 Impact factor: 2.778

6. Statins and the risk of dementia.

Authors: H Jick; G L Zornberg; S S Jick; S Seshadri; D A Drachman
Journal: Lancet Date: 2000-11-11 Impact factor: 79.321

7. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.

Authors: H Mabuchi; J Koizumi; M Shimizu; K Kajinami; S Miyamoto; K Ueda; T Takegoshi
Journal: Am J Cardiol Date: 1998-12-15 Impact factor: 2.778

Low-density lipoprotein apheresis in the treatment of atherosclerosis and other potential uses.

Review 1. Idiopathic sudden sensorineural hearing loss.

Review 2. H.E.L.P. apheresis therapy in the treatment of severe hypercholesterolemia: 10 years of clinical experience.

3. The Microspheres based Detoxification System (MDS). A new extracorporeal blood purification technology based on recirculated microspherical adsorbent particles.

4. Changes in bradykinin and prostaglandins plasma levels during dextran-sulfate low-density-lipoprotein apheresis.

5. Low-density lipoprotein apheresis therapy during pregnancy.

6. Statins and the risk of dementia.

7. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group.

8. Low-density lipoprotein subclass patterns and risk of myocardial infarction.

9. Improvement of coronary vasodilatation capacity through single LDL apheresis.

Review 10. Did grandma give you heart disease? The new battle against coronary artery disease.

1. Current view: indications for extracorporeal lipid apheresis treatment.